What is HC Wainwright’s Forecast for CADL FY2024 Earnings?

Candel Therapeutics, Inc. (NASDAQ:CADL) – Equities research analysts at HC Wainwright increased their FY2024 EPS estimates for Candel Therapeutics in a report released on Wednesday, December 18th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($1.59) per share for the year, up from their prior forecast of ($1.65). HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Candel Therapeutics’ Q4 2024 earnings at ($0.27) EPS and FY2025 earnings at ($1.35) EPS.

Candel Therapeutics Price Performance

CADL stock opened at $8.75 on Friday. The stock has a market cap of $284.17 million, a PE ratio of -5.06 and a beta of -0.95. Candel Therapeutics has a 12 month low of $1.06 and a 12 month high of $14.60. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 1.66. The company has a 50-day moving average price of $5.46 and a 200 day moving average price of $6.05.

Insider Buying and Selling

In other Candel Therapeutics news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the company’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $6.05, for a total transaction of $90,750.00. Following the sale, the insider now owns 944,873 shares in the company, valued at $5,716,481.65. This represents a 1.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CTO Seshu Tyagarajan sold 20,392 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $4.56, for a total value of $92,987.52. Following the completion of the sale, the chief technology officer now directly owns 125,657 shares in the company, valued at $572,995.92. This represents a 13.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,127 shares of company stock valued at $349,911 in the last ninety days. Company insiders own 41.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CADL. Cubist Systematic Strategies LLC purchased a new stake in shares of Candel Therapeutics during the 2nd quarter worth $162,000. Rhumbline Advisers acquired a new stake in Candel Therapeutics in the second quarter valued at $143,000. Point72 DIFC Ltd purchased a new stake in Candel Therapeutics during the 2nd quarter worth about $31,000. Bank of New York Mellon Corp acquired a new position in shares of Candel Therapeutics during the 2nd quarter worth about $338,000. Finally, MetLife Investment Management LLC purchased a new position in shares of Candel Therapeutics in the 3rd quarter valued at about $87,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.